Researchers in Germany have identified a rare mutation in the GPX4 enzyme that disables its protective role in neurons, allowing toxic lipid peroxides to damage cell membranes and trigger ferroptotic cell death. Studies in patient-derived cells and mice show a pattern of neurodegeneration that resembles changes seen in Alzheimer’s disease and other dementias.
A research team led by Prof. Marcus Conrad at Helmholtz Munich and the Technical University of Munich has described how a rare genetic mutation in the selenoenzyme glutathione peroxidase 4 (GPX4) can drive neuronal loss in a severe early childhood dementia.
According to Helmholtz Munich and partner institutions, GPX4 normally shields neurons from ferroptosis, a form of regulated cell death, by inserting a short protein loop – likened to a "fin" – into the inner side of the neuronal cell membrane. This fin-like loop enables the enzyme to detoxify lipid peroxides, reactive molecules that would otherwise damage the membrane and initiate ferroptosis.
The investigation originated with three children in the United States who suffer from an extremely rare form of early childhood dementia, all of whom carry the same R152H point mutation in the GPX4 gene. Using cells from one affected child, the researchers reprogrammed them into a stem‑cell‑like state and then differentiated them into cortical neurons and three‑dimensional brain‑like structures known as brain organoids, to study how the mutation alters GPX4 function.
"GPX4 is a bit like a surfboard," Conrad said, in comments released through Helmholtz Munich and TUM. "With its fin immersed into the cell membrane, it rides along the inner surface and swiftly detoxifies lipid peroxides as it goes." In children with the R152H mutation, this fin-like loop is reshaped. The altered enzyme can no longer insert properly into the membrane, leaving lipid peroxides to accumulate. This causes membrane damage, triggers ferroptosis and ultimately leads to neuron loss.
To examine the effects in the whole organism, the team introduced the R152H variant into a mouse model, altering GPX4 in defined populations of nerve cells. The mice gradually developed marked motor impairments, significant neuron loss in the cerebral cortex and cerebellum, and pronounced neuroinflammatory responses. Researchers report that these features closely matched observations in the affected children and resembled profiles seen in neurodegenerative diseases.
Proteomic analyses in the experimental models revealed shifts in protein levels that overlap with patterns described in Alzheimer’s disease and related disorders, suggesting that ferroptotic stress may contribute more broadly to common dementias. The authors of the Cell paper interpret their data as evidence that ferroptosis can act as a driving force behind neuronal death, rather than merely a byproduct of neurodegeneration.
The study, published in Cell under the title "A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis," emphasizes an alternative starting point for neurodegenerative cascades: initial damage to neuronal membranes caused by unchecked lipid peroxidation, rather than the accumulation of protein aggregates alone.
Early-stage experiments using ferroptosis inhibitors in cell cultures and in mouse models slowed neuronal death, providing proof of principle that blocking this pathway might be protective. However, the researchers stress that these findings remain at the level of basic research and are far from clinical application. Co‑author Dr. Tobias Seibt and colleagues caution that while targeting ferroptosis represents a promising avenue, further studies are needed before any potential therapies can be tested in patients.
The work reflects more than a decade of international collaboration, bringing together expertise in human genetics, structural biology, proteomics and neuroscience across multiple centers, including Helmholtz Munich, the Technical University of Munich and clinical partners.
